Azitra is trading 6.9% up now at $0.17, with the move appearing primarily tied to improving broad-market sentiment rather than a fresh company-specific catalyst.
- Major U.S. indices are higher, while biotechnology is also strengthening as investors rotate toward risk assets.
- Azitra’s latest identifiable company-related item is its H.C. Wainwright conference presentation, announced for September 14–16, rather than a new September 17 announcement.